Exicure, Inc. (NASDAQ:XCUR) Brief Interest Update
Exicure, Inc. (NASDAQ:XCUR – Get a rating) was the target of a sharp decline in short-term interest in June. As of June 30, there were short interests totaling 242,300 shares, down 94.3% from the June 15 total of 4,220,000 shares. Based on an average trading volume of 425,200 shares, the day-to-cover ratio is currently 0.6 days. Currently, 10.7% of the company’s shares are sold short.
XCUR Stock opened at $1.91 on Thursday. The stock has a market capitalization of $7.81 million, a PE ratio of -0.10 and a beta of 1.83. Exicure has a 12 month minimum of $1.85 and a 12 month maximum of $59.40. The stock’s 50-day simple moving average is $4.62 and its 200-day simple moving average is $5.44.
Exicure (NASDAQ:XCUR – Get a rating) last released its quarterly results on Monday, May 16. The company reported ($2.10) earnings per share for the quarter. The company had revenue of $2.57 million in the quarter. As a group, analysts predict Exicure to post -4.2 EPS for the current year.
In other Exicure news, Director Bali Muralidhar acquired 1,472,126 shares in a deal that took place on Thursday, May 19. The shares were acquired at an average cost of $0.19 per share, with a total value of $279,703.94. Following the transaction, the administrator now owns 8,449,126 shares of the company, valued at approximately $1,605,333.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, accessible via this link. Company insiders own 8.40% of the company’s shares.
Hedge funds and other institutional investors have recently increased or reduced their stakes in the company. Privium Fund Management UK Ltd bought a new position in shares of Exicure during Q4 worth $332,000. UBS Group AG increased its shareholding in Exicure by 1,766.7% in the 1st quarter. UBS Group AG now owns 186,674 shares of the company worth $37,000 after purchasing an additional 176,674 shares last quarter. Goldman Sachs Group Inc. increased its stake in Exicure shares by 329.2% in Q1. Goldman Sachs Group Inc. now owns 147,703 shares of the company worth $29,000 after buying an additional 113,293 shares last quarter. Finally, Sigma Planning Corp increased its stake in Exicure shares by 206.1% in the 1st quarter. Sigma Planning Corp now owns 519,500 shares of the company worth $104,000 after buying an additional 349,800 shares in the last quarter. 41.68% of the shares are currently held by hedge funds and other institutional investors.
About Exicure (Get a rating)
Exicure, Inc, a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A which is in preclinical studies for neuropathic and chronic pain. The company has entered into a collaboration, option and license agreement with AbbVie Inc to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen SA for the research, development and marketing of new spherical nucleic acids for Huntington’s disease and Angelman syndrome.
Get news and reviews for Exicure Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Exicure and related companies with MarketBeat.com’s free daily email newsletter.